Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignances

30 Jan 2025

Abstract excerpt

Most CAR-T therapies rely on genetic T cell engineering with integrating viral vectors that, although effective, are associated with prohibitive costs. Here we have generated TranspoCART19 cells, a fully functional 4-1BB second-generation CAR-T cell product targeting CD19, fused to a truncated version of the human EGFR (hEGFRt) as reporter gene and safety switch, based on the Sleeping Beauty transposon delivery...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40034423
DOI: 10.1016/j.omtm.2025.101425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation and GMP scale-up of human CAR-T cells using non-viral Sleeping Beauty transposons for B cell malignancesPMID 40034423Read ↗

A meta-analysis on safety and efficacy of CD19 directed CAR T-cells generated using sleeping beauty transposon systemSemantic proximity Read ↗

Sleeping Beauty System to Redirect T-cell Specificity for Human ApplicationsSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T <sub>SCM</sub> cells using <i>qCART</i> , the <i>Quantum pBac</i> -based CAR-T systemSemantic proximity Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection.Semantic proximity Read ↗

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?Semantic proximity Read ↗

Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospectsSemantic proximity Read ↗

Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.Semantic proximity Read ↗

Redirecting Specificity of T-Cell Populations For CD19 Using the <i>Sleeping Beauty</i> SystemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.